Evaluation of Panbio rapid antigen test for SARS‐CoV‐2 in symptomatic patients and their contacts: a multicenter study

Evaluation of Panbio rapid antigen test for SARS‐CoV‐2 in symptomatic patients and their contacts: a multicenter study

Background: Point-of-care rapid tests to identify SARS-CoV-2 can have clinical benefits. Methods: A cross-sectional study in adults visiting emergency services or screening sites of referral hospitals for COVID-19 to validate the diagnostic performance of a rapid antigen test for SARS-CoV-2 (Abbott&...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ireri Thirion-Romero, Dr. Selene Guerrero-Zúñiga, Dr. Alexandra Arias-Mendoza, Dr. Dora Patricia Cornejo-Juárez, Dr. Patricia Meza-Meneses, Dr. Darwin Stalin Torres-Erazo, Dr. Thierry Hernández-Gilsoul, Dr. Arturo Galindo-Fraga, Dr. Isabel Villegas-Mota, Dr. Jesús Sepúlveda-Delgado, Dr. Santiago Ávila-Ríos, Dr. Eduardo Becerril-Vargas, Rosario Fernández-Plata, TIT Midori Pérez-Kawabe, Dr. Ana Coeto-Cano, Dr. Joel Armando Vázquez-Pérez, Dr. Simón Kawa-Karasik, Dr. Gustavo Reyes-Terán, Dr. José Rogelio Pérez-Padilla
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
COVID-19
SARS-CoV-2
point of care test
rapid antigen test
Panbio
Abbott
Infectious and parasitic diseases
RC109-216
Acceso en línea:https://doaj.org/article/36c9ec7fdecf47a98ba2299bde37eda2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Background: Point-of-care rapid tests to identify SARS-CoV-2 can have clinical benefits. Methods: A cross-sectional study in adults visiting emergency services or screening sites of referral hospitals for COVID-19 to validate the diagnostic performance of a rapid antigen test for SARS-CoV-2 (Abbott's Panbio) compared with reverse transcription-polymerase chain reaction (RT-PCR) testing. Tests were performed by health personnel in a routine situation during a COVID-19 outbreak. Results: A total of 1060 participants (mean age 47, 46% with a self-reported comorbidity) were recruited from 8 hospitals in Mexico. Participants provided 1060 valid Panbio rapid test-RT-PCR test pairs with 45% testing positive in the RT-PCR. Overall sensitivity of the Panbio test was 54.2% (95% CI 51%–57%), and 69.1% (95% CI 66%–73%) for patients during the first week of symptoms. Sensitivity depended on viral load (cycle threshold (Ct) of RT-PCR) and days of symptoms. With a Ct ≤25, sensitivity was 82% (95% CI, 76%–87%). Specificity of the Panbio test was >97.8% in all groups. Conclusions: The Panbio rapid antigen test for SARS-CoV-2 had good specificity but low sensitivity. A negative test requires confirmation with RT-PCR, especially for testing after the first week of symptoms.

Ejemplares similares